Tekturna HCT, a single-pill combination of aliskiren—the first and only approved direct renin inhibitor—and hydrochlorothiazide (HCTZ) has been approved as initial therapy for patients who are likely to need multiple drugs to achieve their BP.
FDA approval of Tekturna HCT as initial therapy was based on study data showing that the combined treatment offered greater BP reductions than either drug alone, according to a statement released by the drug’s maker, Novartis, of East Hanover, N.J.
Tekturna HCT is available in four strengths as tablets containing aliskiren and hydrochlorothiazide: 150 mg/12.5 mg tablets, 150 mg/25 mg tablets, 300 mg/12.5 mg tablets and 300 mg/25 mg tablets.
Continue Reading
